Project: My condition, my DNA

Taking the patient and family perspective to the centre of genomic sequencing policy-making

If you would like to see more projects like this, please donate using the button above


In February 2015 we launched a Patient Charter called "Genome sequencing: What do patients think?".

The charter was generated from the views and opinions that we gained from a series of engagement events where patients and families gave us their views and priorities on genomic sequencing. Topics were introduced to patients and families through case-studies and scenarios of families like theirs in free online applications. This work was part of the My Condition, My DNA project.


My Condition, My DNA is a programme funded by the British In Vitro Diagnostics Association (BIVDA), the Medical Research Council (MRC) and the Wellcome Trust. Genetic Alliance UK will be working to bring the patient and family perspective on the ethical and societal issues surrounding genomic sequencing to the heart of decision-making about its uptake in the NHS.

What is genomic sequencing?

Genomic sequencing technologies can determine the exact order of letters – As, Cs, Gs and Ts – along a piece of DNA. Whilst ‘traditional’ DNA sequencing methods involve the analysis of one gene after another to try and identify where a genetic alteration may be, new methods are allowing multiple genes to be sequenced simultaneously as well as an individual’s whole genome.

The information provided by new genomic sequencing methods could aid diagnostic testing, targeted treatment, gene therapy and the production of therapeutic proteins.

These technologies are in the early stages of being introduced to genetic laboratories and in 2013 the UK Government committed to introducing new genomic sequencing into mainstream clinical practice. Later this year, NHS England will be reviewing the use of genetic sequencing technology for genetic testing and will be reconfiguring laboratory services.

Genomic sequencing offers great potential for the effective diagnosis and management of many genetic conditions yet it raises many ethical and societal issues that are important to patients and their families, who will be the end-beneficiaries of such technologies.

For example, who should have access to the data generated by genomic sequencing? If genomic sequencing reveals a clinical finding that is not related to the condition being tested for, should this information be relayed to the patient? What level of follow-up counselling should be provided after genomic sequencing results have been communicated? These are just some of the questions where we think the views of patients and families affected by genetic conditions are important.